• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Vaxcyte Inc.

    2/25/25 4:42:05 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCVX alert in real time by email
    S-8 1 d916489ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 25, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    VAXCYTE, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   46-4233385

    (State or other jurisdiction of

    Incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    825 Industrial Road, Suite 300

    San Carlos, California 94070

    (Address of principal executive offices) (Zip code)

    2020 Equity Incentive Plan

    (Full titles of the plans)

    Grant E. Pickering

    Chief Executive Officer

    Vaxcyte, Inc.

    825 Industrial Road, Suite 300

    San Carlos, California 94070

    (650) 837-0111

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Michael J. Hong

    Skadden, Arps, Slate, Meagher & Flom LLP

    One Manhattan West

    New York, New York 10001

    Telephone: (212) 735-3000

    Facsimile: (212) 735-2000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    Vaxcyte, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering 6,244,651 shares of its Common Stock issuable to eligible persons under the Registrant’s 2020 Equity Incentive Plan, which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s Registration Statements on Form S-8 filed on June  12, 2020 (File No. 333-239135), March  29, 2021 (File No. 333-254824), February  28, 2022 (File No. 333-263093), February  27, 2023 (File No. 333-270064) and February  27, 2024 (File No. 333-277413) (together, the “Prior Registration Statements”).


    PART II

     

    ITEM 3.

    INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

    Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated by reference herein. The Registrant hereby incorporates by reference into this Registration Statement the following documents filed by it with the Securities and Exchange Commission (the “SEC”):

     

    (a)    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 25, 2025; and
    (b)    The description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-39323) filed with the SEC on June 9, 2020, as updated by Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 and any amendments or reports filed for the purpose of updating such description.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    ITEM 8.

    EXHIBITS

     

              Incorporated by Reference
    Exhibit    Description   

    Schedule/

    Form

       File Number    Exhibits    Filing Date
    4.1    Amended and Restated Certificate of Incorporation of Vaxcyte, Inc., as amended.    8-K    001-39323    3.1    June 16, 2020
    4.2    Amended and Restated Bylaws of Vaxcyte, Inc., as amended.    10-Q    001-39323    3.2    November 6, 2023
    4.3    Form of Pre-Funded Warrant.    8-K    001-39323    4.1    January 13, 2022
    4.4    Form of Pre-Funded Warrant.    8-K    001-39323    4.1    October 27, 2022
    4.5    Form of Pre-Funded Warrant.    8-K    001-39323    4.1    April 20, 2023
    4.6    Form of Pre-Funded Warrant.    8-K    001-39323    4.1    January 31, 2024
    4.7    Form of Pre-Funded Warrant.    8-K    001-39323    4.1    September 6, 2024
    5.1    Opinion of Skadden, Arps, Slate, Meagher & Flom LLP.             X
    23.1    Consent of Independent Registered Public Accounting Firm.             X
    23.2    Consent of Skadden, Arps, Slate, Meagher & Flom LLP (reference is made to Exhibit 5.1).             X
    24.1    Power of Attorney (reference is made to the signature page hereto).             X
    99.1    2020 Equity Incentive Plan.    10-Q    001-39323    10.1    August 8, 2023
    99.2    Form of Stock Option Grant Notice and Stock Option Agreement.    10-Q    001-39323    10.2    August 8, 2023
    99.3    Form of Restricted Stock Unit Grant Notice.    10-Q    001-39323    10.2    May 9, 2022
    99.4    Form of Non-U.S. Stock Option Grant Notice and Stock Option Agreement.    10-K    001-39323    10.26    February 27, 2023
    99.5    Form of Non-U.S. Restricted Stock Unit Grant Notice.    10-K    001-39323    10.27    February 27, 2023
    107    Filing Fee Table.             X

     

    X

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Carlos, State of California, on February 25, 2025.

     

    VAXCYTE, INC.
    By:   /s/ Grant E. Pickering
        Grant E. Pickering
        Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Grant E. Pickering and Andrew Guggenhime, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.


    Signature

      

    Title

     

    Date

    /s/ Grant E. Pickering

    Grant E. Pickering

      

    Chief Executive Officer and Director

    (Principal Executive Officer)

      February 25, 2025

    /s/ Andrew Guggenhime

    Andrew Guggenhime

      

    President and Chief Financial Officer

    (Principal Financial Officer)

      February 25, 2025

    /s/ Elvia Cowan

    Elvia Cowan

      

    Senior Vice President, Finance

    (Principal Accounting Officer)

      February 25, 2025

    /s/ Carlos Paya

    Carlos Paya, M.D., Ph.D.

      

    Director

      February 25, 2025

    /s/ Annie Drapeau

    Annie Drapeau

      

    Director

      February 25, 2025

    /s/ John Furey

    John Furey

      

    Director

      February 25, 2025

    /s/ Halley Gilbert

    Halley Gilbert

      

    Director

      February 25, 2025

    /s/ Peter Hirth

    Peter Hirth, Ph.D.

      

    Director

      February 25, 2025

    /s/ Jacks Lee

    Jacks Lee

      

    Director

      February 25, 2025

    /s/ Teri Loxam

    Teri Loxam

      

    Director

      February 25, 2025

    /s/ Heath Lukatch

    Heath Lukatch, Ph.D.

      

    Director

      February 25, 2025
    Get the next $PCVX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PCVX

    DatePrice TargetRatingAnalyst
    1/7/2026$90.00 → $110.00Buy
    Needham
    9/12/2025$38.00Neutral
    Goldman
    4/22/2025Overweight
    Cantor Fitzgerald
    12/20/2024$135.00Buy
    Goldman
    12/7/2023$69.00Buy
    Mizuho
    4/18/2023Outperform
    TD Cowen
    1/3/2023$52.00 → $58.00Buy
    Needham
    12/15/2022$66.00Buy
    Guggenheim
    More analyst ratings

    $PCVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Pickering Grant gifted 100,000 shares, decreasing direct ownership by 20% to 400,908 units (SEC Form 4)

    4 - Vaxcyte, Inc. (0001649094) (Issuer)

    1/16/26 5:10:28 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CFO Guggenhime Andrew gifted 61,850 shares and received a gift of 61,850 shares, decreasing direct ownership by 50% to 62,459 units (SEC Form 4)

    4 - Vaxcyte, Inc. (0001649094) (Issuer)

    1/16/26 5:09:55 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Brandicourt Olivier was granted 1,357 shares, increasing direct ownership by 118% to 2,505 units (SEC Form 4)

    4 - Vaxcyte, Inc. (0001649094) (Issuer)

    1/16/26 5:08:29 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Vaxcyte with a new price target

    Needham reiterated coverage of Vaxcyte with a rating of Buy and set a new price target of $110.00 from $90.00 previously

    1/7/26 8:03:12 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Vaxcyte with a new price target

    Goldman initiated coverage of Vaxcyte with a rating of Neutral and set a new price target of $38.00

    9/12/25 7:53:21 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Vaxcyte

    Cantor Fitzgerald initiated coverage of Vaxcyte with a rating of Overweight

    4/22/25 7:35:12 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    SEC Filings

    View All

    SEC Form 8-K filed by Vaxcyte Inc.

    8-K - Vaxcyte, Inc. (0001649094) (Filer)

    2/2/26 4:01:31 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Vaxcyte Inc.

    424B5 - Vaxcyte, Inc. (0001649094) (Filer)

    1/30/26 5:12:46 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Vaxcyte Inc.

    424B5 - Vaxcyte, Inc. (0001649094) (Filer)

    1/29/26 4:01:12 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

    SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the cons

    2/5/26 4:05:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,650,000 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were $632.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte

    2/2/26 4:05:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte Announces Pricing of $550 Million Public Offering

    SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering price of $50.00 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be $550 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its commo

    1/29/26 11:33:04 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

    SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    11/14/24 5:46:11 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

    SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    11/14/24 2:53:06 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

    SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    11/12/24 10:34:18 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Financials

    Live finance-specific insights

    View All

    Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

    -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

    3/31/25 7:00:00 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

    SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants. To participate in the conference call, p

    3/30/25 5:00:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

    SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVXQ424. A live webcast

    2/12/25 4:05:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Leadership Updates

    Live Leadership Updates

    View All

    Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

    Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study Modified VAX-31 Infant Phase 2 Dose-Finding Study Advanced to Third and Final Stage Company Expects to Initiate VAX-31 Adult Pivotal, Non-Inferiority Study in December 2025 with Topline Data in 2026 Company Establishing Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy, Aligned with Administration's Focus on Strengthening Domestic Biomanufacturing and Representing up to $1 Billion in Manufacturing and Servi

    11/4/25 4:05:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

    SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

    5/1/25 8:00:29 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte Appoints John Furey to Board of Directors

    SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. "We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24

    7/2/24 8:30:00 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care